Chemomab Therapeutics Ltd.
CMMBNasdaqCIK 1534248HealthcareFiscal year ends Dec 31
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: Q1 FY2023
Three months to Mar 31, 2023, against the same quarter a year earlier.
- Revenuenot reported (Revenue not reported)No year-earlier figure to compare
- Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
- Operating marginnot reported (Operating income and Revenue not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue not reported)No year-earlier figure to compare
- Diluted EPS$0.04Diluted EPS, Q1 FY2023, three months to 2023-03-31$0.04 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure+81.8% on a year earlier - Free cash flow−$7.2mFree cash flow, Q1 FY2023, three months to 2023-03-31. operating cash flow − capital expenditureOperating cash flow: −$7.2m. XBRL concept
us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Capital expenditure: $1.0k. XBRL conceptus-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure−92.9% on a year earlier
Last eight quarters
Full statements| Line item | Unit | Q2 FY20212021-06-30 | Q3 FY20212021-09-30 | Q4 FY20212021-12-31 | Q1 FY20222022-03-31 | Q2 FY20222022-06-30 | Q3 FY20222022-09-30 | Q4 FY20222022-12-31 | Q1 FY20232023-03-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $k | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | 0.01Diluted EPS, Q2 FY2021, three months to 2021-06-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure | 0.01Diluted EPS, Q3 FY2021, three months to 2021-09-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure | not reported (Diluted EPS not reported) | 0.02Diluted EPS, Q1 FY2022, three months to 2022-03-31$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure | 0.03Diluted EPS, Q2 FY2022, three months to 2022-06-30$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2022-08-12, accession 0001178913-22-003074.Report this figure | 0.04Diluted EPS, Q3 FY2022, three months to 2022-09-30$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2022-11-10, accession 0001178913-22-003931.Report this figure | not reported (Diluted EPS not reported) | 0.04Diluted EPS, Q1 FY2023, three months to 2023-03-31$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure | |
| Free cash flow | $k | (5,709)Free cash flow, Q2 FY2021, three months to 2021-06-30. operating cash flow − capital expenditureOperating cash flow: −$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2022-08-12, accession 0001178913-22-003074. Derived: 6-month figure less the 3-month figure.Capital expenditure: $102.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2022-08-12, accession 0001178913-22-003074. Derived: 6-month figure less the 3-month figure.Report this figure | (2,580)Free cash flow, Q3 FY2021, three months to 2021-09-30. operating cash flow − capital expenditureOperating cash flow: −$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2022-11-10, accession 0001178913-22-003931. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2022-11-10, accession 0001178913-22-003931. Derived: 9-month figure less the 6-month figure.Report this figure | (3,028)Free cash flow, Q4 FY2021, three months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2024-03-28, accession 0001178913-24-001124. Derived: 12-month figure less the 9-month figure.Capital expenditure: $134.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2024-03-28, accession 0001178913-24-001124. Derived: 12-month figure less the 9-month figure.Report this figure | (3,725)Free cash flow, Q1 FY2022, three months to 2022-03-31. operating cash flow − capital expenditureOperating cash flow: −$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Capital expenditure: $14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure | (5,712)Free cash flow, Q2 FY2022, three months to 2022-06-30. operating cash flow − capital expenditureOperating cash flow: −$5.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2022-08-12, accession 0001178913-22-003074. Derived: 6-month figure less the 3-month figure.Capital expenditure: $11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2022-08-12, accession 0001178913-22-003074. Derived: 6-month figure less the 3-month figure.Report this figure | (5,297)Free cash flow, Q3 FY2022, three months to 2022-09-30. operating cash flow − capital expenditureOperating cash flow: −$5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2022-11-10, accession 0001178913-22-003931. Derived: 9-month figure less the 6-month figure.Capital expenditure: $42.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2022-11-10, accession 0001178913-22-003931. Derived: 9-month figure less the 6-month figure.Report this figure | (5,704)Free cash flow, Q4 FY2022, three months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2025-04-04, accession 0001178913-25-001205. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2025-04-04, accession 0001178913-25-001205. Derived: 12-month figure less the 9-month figure.Report this figure | (7,187)Free cash flow, Q1 FY2023, three months to 2023-03-31. operating cash flow − capital expenditureOperating cash flow: −$7.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Capital expenditure: $1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-05-11, accession 0001178913-23-001807.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | 0.06Diluted EPS, FY2021, twelve months to 2021-12-31$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 20-F filed 2024-03-28, accession 0001178913-24-001124.Report this figure | 0.12Diluted EPS, FY2022, twelve months to 2022-12-31$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 20-F filed 2025-04-04, accession 0001178913-25-001205.Report this figure | 0.10Diluted EPS, FY2023, twelve months to 2023-12-31$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure | 0.04Diluted EPS, FY2024, twelve months to 2024-12-31$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure | 0.02Diluted EPS, FY2025, twelve months to 2025-12-31$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure | |
| Free cash flow | $m | (12.6)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$12.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2024-03-28, accession 0001178913-24-001124.Capital expenditure: $239.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2024-03-28, accession 0001178913-24-001124.Report this figure | (20.4)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$20.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2025-04-04, accession 0001178913-25-001205.Capital expenditure: $68.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2025-04-04, accession 0001178913-25-001205.Report this figure | (23.6)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$23.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2026-03-23, accession 0001178913-26-001593.Capital expenditure: $3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure | (15.4)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$15.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2026-03-23, accession 0001178913-26-001593.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure | (11.1)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$11.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 20-F filed 2026-03-23, accession 0001178913-26-001593.Capital expenditure: $3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 20-F filed 2026-03-23, accession 0001178913-26-001593.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | 2026-06-30 | $154.4k | 95,311 | Added+31,129 | |
| ADAR1 Capital Management, LLC | 2026-06-30 | $129.6k | 80,000 | Unchanged | |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 2026-06-30 | $100.0k | 61,710 | Unchanged | |
| Ikarian Capital, LLC | 2026-06-30 | $83.9k | 51,793 | Unchanged | |
| RHUMBLINE ADVISERS | 2026-06-30 | $49.5k | 30,529 | Added+12,163 | |
| XTX Topco Ltd | 2026-06-30 | $25.9k | 15,987 | Reduced−2,642 | |
| Philadelphia Investment Partners, LLC | 2026-06-30 | $24.3k | 15,000 | Added+6,800 | |
| Lido Advisors, LLC | 2026-06-30 | $23.2k | 14,341 | New+14,341 | |
| BNP PARIBAS FINANCIAL MARKETS | 2026-06-30 | $11.0k | 6,805 | Reduced−1,620 | |
| GAMMA Investing LLC | 2026-06-30 | $7.7k | 4,740 | Reduced−2,839 |
Recent filings
All 360 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1917:28 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-19 | 0001178913-26-004796 |
| 2026-09-3016:05 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-30 | 0001178913-26-004676 |
| 2026-09-0916:00 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-26-106301 |
| 2026-08-1909:16 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-30 | 0001178913-26-004193 |
| 2026-07-1616:05 ET | SCHEDULE 13D | Ownership report, active investor | 0001104659-26-084244 |
| 2026-07-0807:34 ET | 6-K | Report of a foreign private issuerPeriod 2026-07-08 | 0001178913-26-003442 |
| 2026-06-0216:03 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-02 | 0001178913-26-003058 |
| 2026-05-1408:00 ET | 6-K | Report of a foreign private issuerPeriod 2026-05-14 | 0001178913-26-002672 |
| 2026-05-0617:03 ET | 6-K | Report of a foreign private issuerPeriod 2026-05-06 | 0001178913-26-002423 |
| 2026-04-2816:06 ET | 6-K | Report of a foreign private issuerPeriod 2026-04-28 | 0001178913-26-002274 |
Latest annual report
Form 20-F for the fiscal year ended Dec 31, 2025Filed Mar 23, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1534248
- Tickers
- CMMB
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- L3
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Former names
- Anchiano Therapeutics Ltd. (to 2021-03-17); BioCancell Ltd. (to 2015-11-03)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:20 ET. Listed shows no prices and gives no investment advice.